Logo
x

Search

Subscribe Now

Psoriatic Arthritis

Disease of the Month – Psoriatic arthritis

Disease of the Month – Psoriatic arthritis

  • October 16, 2024
AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021

AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis...

  • November 10, 2021
AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis

AbbVie's Rinvoq (upadacitinib) Receives the Health Canada's Approval for the Treatment of Psoriatic Arthritis

  • June 8, 2021
AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

AbbVie Submits Regulatory Applications to the US FDA and EMA for Skyrizi (risankizumab) to Treat Psoriatic Arthritis

  • April 8, 2021
Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

Johnson & Johnson Report Long-Term Data of Tremfya (guselkumab) in P-III DISCOVER-2 Study for Active Psoriatic Arthritis

  • March 17, 2021
AbbVie's Rinvoq (upadacitinib) Receives the EC's Approval for Psoriatic Arthritis and Ankylosing Spondylitis

AbbVie's Rinvoq (upadacitinib) Receives the EC's Approval for Psoriatic Arthritis and Ankylosing Spondylitis

  • January 27, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.